The PCSK9 Revolution in Cholesterol Reduction

Faculty

Steven A. Grover, MD, MPA, FRCP, FRCPC
Professor, Departments of Medicine and Epidemiology & Biostatistics, McGill University
Founding Director, Cardiovascular Health Improvement Program, McGill University
Founding Director, Centre for the Analysis of Cost-Effective Care, Montreal General Hospital
Founding Director, Centre for Cardiovascular Risk Assessment, Montreal General Hospital
Senior Physician, Montreal General Hospital
McGill University Health Centre
Consulting Physician, Department of Community Health, Montreal, Quebec

Robert A. Hegele, MD, FRCP, FACP
Jacob J. Wolfe Distinguished Medical Research Chair
Edith Schmidt Vinet Canada Research Chair (Tier 1) in Human Genetics
Martha Blackburn Chair in Cardiovascular Research
Distinguished University Professor of Medicine and Biochemistry, University of Western Ontario

G. B. John Mancini, MD, FRCP, FACP, FACC
Professor of Medicine; University of British Columbia; Department of Medicine; Division of Cardiology
Research Director, Division of Cardiology; Director, Cardiovascular Imaging Research Core Laboratory (CIRC); President, Vancouver Hospital Medical, Dental and Allied Staff; Staff Cardiologist, VH Cardiology Clinics and Cardiac Computed Tomographic Angiography Program; Staff Cardiologist, St. Paul’s Hospital Healthy Heart/Prevention Clinic

Ruth McPherson, BSc, MSc, PhD, MD, FRCP, FACC
Director, Dwyer Canadian Cardiovascular Genetics Centre
Director, Atherogenomics Laboratory and Lipid Clinic
Director of Research, Division of Cardiology
University of Ottawa Heart Institute
Professor, Departments of Medicine and Biochemistry, University of Ottawa

Nabil G. Seidah, C.M., O.Q., PhD, MSRC
Director, Biochemical Neuroendocrinology research unit;
Full IRCM Research Professor
Full research professor, Department of Medicine (accreditation in molecular biology and biochemistry), Université de Montréal
Adjunct Professor, Department of Medicine (Division of Experimental Medicine), McGill University
Canada Research Chairholder in Precursor Proteolysis 2011 Wilner-Penfield Prix du Québec
Member, Order of Canada
Officer, Ordre national du Québec
Fellow, Royal Society of Canada

Jean-Claude Tardif, MD, FRCP, FACC, FAHS
Scientific Director, Montreal Heart Institute
Coordinating Center (MHIIC)
Full Professor, Faculty of Medicine, Université de Montréal
Canada Research Chair in Translational and Personalized Medicine
Pfizer Chair in Atherosclerosis, Université de Montréal
Chair, Steering Committee, Canadian Atherosclerosis Imaging Network (CAIN)
President, Medical Imaging Trial Network of Canada (MITNEC)

Subodh Verma, MD, PhD, FRCP, FAHA
Cardiac Surgeon, St. Michael’s Hospital
Professor of Surgery and Pharmacology, University of Toronto
Canada Research Chair in Atherosclerosis, Toronto, Ontario

Lawrence A. Leiter, MD, FRCP, FACP, FAHA
Director, Lipid Clinic, St. Michael’s Hospital
Professor of Medicine and Nutritional Sciences, University of Toronto
Toronto, Ontario

Chair

Co-Chair

Agenda

8:00 a.m. Registration and breakfast

9:00 a.m. Welcome and program objectives

Dr. Lawrence Leiter (Chair)

Session 1: What is PCSK9 and why is it important?

9:10 a.m. The discovery of PCSK9: A Canadian legacy

Dr. Nabil G. Seidah

9:30 a.m. PCSK9 inhibitors: How do they work?

Dr. Ruth McPherson

9:50 a.m. Genetics of cholesterol and FH: What you must know

Dr. Robert Hegele

10:10 a.m. Panel discussion / Q&A

10:40 a.m. Refreshment break

Session 2: Clinical Translational Studies

11:10 a.m. Why do we need statin alternatives?

Dr. G. B. John Mancini

11:30 a.m. PCSK9 inhibitors: Results of recent studies

Dr. Lawrence Leiter

11:50 a.m. Ongoing clinical trials of PCSK9 inhibitors

Dr. Jean-Claude Tardif

12:10 p.m. Panel discussion / Q&A

12:40 p.m. Lunch

Session 3: Practical Application

1:30 p.m. Injectable cholesterol lowering therapies: What are the issues?

Dr. Shafiq Qaadri

1:50 p.m. Lipid guidelines: Where will PCSK9 Inhibitors likely fit in?

Dr. Ruth McPherson

2:10 p.m. The pharmacoeconomics of lipid lowering: What is the bar for a new therapy?

Dr. Steven Grover

2:30 p.m. Panel discussion / Q&A

3:00 p.m. Closing and program evaluation

Dr. Subodh Verma (Co-Chair)

To register please go to www.eply.com/PCSK9

Registration fee: $39 (includes HST)
(covers attendance at full day program, meeting materials, all meals and refreshments)

For more information please contact S&L Solutions at 289-232-4229 or slsolutions@rogers.com

This program is supported by educational grants from:

GOLD:

AMGEN

SILVER:

Pfizer

SANOFI